Responder patients 2 and 6 and nonresponder patient 3 exhibited a consistently notable trend of enrichment in the naïve CD4+ T cell population at the baseline around leukemia cells compared with the end of the second treatment cycle (Fig. 4B). The gene discussed is CD4; the disease is leukemia.